Joachim Sieper

Q: What Schools Are Affiliated With Joachim Sieper

Joachim Sieper is affiliated with the following schools: Humboldt University of Berlin, University of Cologne, Free University of Berlin

Joachim Sieper's AcademicInfluence.com Rankings

Joachim Sieper

Philosophy

#3649

World Rank

#5860

Historical Rank

Logic

#1302

World Rank

#2017

Historical Rank

philosophy Degrees

Joachim Sieper

Biology

#4606

World Rank

#6848

Historical Rank

Immunology

#202

World Rank

#211

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Joachim Sieper's Degrees

Doctorate Medicine University of Cologne
PhD Immunology University of Cologne

Why Is Joachim Sieper Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Joachim Sieper's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection (2009) (2650)
What low back pain is and why we need to pay attention (2018) (1853)
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis (2009) (1281)
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial (2002) (1270)
Prevention and treatment of low back pain: evidence, challenges, and promising directions (2018) (1116)
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis (2011) (959)
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. (1998) (935)
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). (2005) (807)
Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group (2009) (781)
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal (2009) (780)
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. (2006) (779)
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis (2008) (744)
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. (2015) (728)
ASAS/EULAR recommendations for the management of ankylosing spondylitis (2005) (719)
Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. (1995) (668)
The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. (2009) (630)
How to diagnose axial spondyloarthritis early (2004) (627)
Ankylosing spondylitis: an overview (2002) (620)
Low back pain: a call for action (2018) (600)
Ankylosing spondylitis. (2007) (547)
Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. (2008) (519)
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. (2000) (514)
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial (2013) (513)
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS) (2009) (510)
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis (2008) (509)
The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? (2005) (507)
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies (2011) (477)
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force (2017) (476)
Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria. (2006) (476)
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1) (2012) (467)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011 (2006) (464)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010 (2011) (464)
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. (2003) (457)
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force (2013) (436)
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis (2003) (427)
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor α blockers in ankylosing spondylitis (2004) (423)
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. (2003) (415)
Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. (2012) (404)
Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. (2005) (403)
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis (2005) (391)
EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice (2015) (390)
2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis (2011) (350)
Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group (2016) (346)
Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. (1994) (336)
Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis— cellularity correlates with the degree of enhancement detected by magnetic resonance imaging (2000) (336)
Rheumatoid arthritis: evaluation of hypervascular and fibrous pannus with dynamic MR imaging enhanced with Gd-DTPA. (1990) (326)
Axial spondyloarthritis (2017) (317)
Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. (2009) (314)
Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. (2008) (313)
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial (2013) (310)
Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis (2011) (310)
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis (2004) (309)
Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort (2012) (300)
TNF signaling drives myeloid-derived suppressor cell accumulation. (2012) (294)
Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response (2011) (284)
MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis (2007) (267)
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab (2005) (266)
Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial (2011) (261)
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. (2003) (253)
Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis (2013) (253)
Ankylosing Spondylitis and Axial Spondyloarthritis. (2016) (245)
Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS) (2014) (244)
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study (2018) (237)
Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes (2007) (235)
Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. (2008) (233)
Concepts and epidemiology of spondyloarthritis. (2006) (228)
The relationship between inflammation and new bone formation in patients with ankylosing spondylitis (2008) (227)
Open label trial of anakinra in active ankylosing spondylitis over 24 weeks (2004) (226)
Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group (2012) (223)
ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis (2010) (214)
Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study (2016) (212)
Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis (2018) (212)
Development and preselection of criteria for short term improvement after anti-TNFα treatment in ankylosing spondylitis (2004) (207)
Effectiveness, Safety, and Predictors of Good Clinical Response in 1250 Patients Treated with Adalimumab for Active Ankylosing Spondylitis (2009) (206)
Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. (2007) (202)
High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis (2011) (201)
Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. (2010) (201)
Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. (2005) (199)
Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage. (1999) (195)
Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials (2013) (194)
Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. (2007) (190)
Radiologic diagnosis and pathology of the spondyloarthropathies. (1998) (190)
Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis (2014) (190)
Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging (2004) (188)
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial (2008) (185)
Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. (1996) (183)
Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis (2007) (183)
Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor α in two patients with early disease and transforming growth factor β in three more advanced cases (2005) (182)
No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial (2006) (181)
Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems (2004) (180)
Symptomatic Efficacy of Etanercept and Its Effects on Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial (2014) (179)
Predicting the outcome of ankylosing spondylitis therapy (2011) (177)
On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, Germany, July 3-6, 1999. (2000) (176)
Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. (1997) (175)
Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor α antibody infliximab (2005) (174)
The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis (2008) (172)
Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care (2004) (172)
Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study (2011) (170)
Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis (2006) (170)
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis (2004) (169)
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and (2018) (168)
Low T cell production of TNFα and IFNγ in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism (2001) (166)
Imaging and scoring in ankylosing spondylitis. (2002) (166)
Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1 (2013) (165)
Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. (2005) (165)
Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. (2006) (164)
Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences (2005) (163)
Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. (2005) (163)
Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS) (2015) (163)
Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography (2013) (162)
Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial (2006) (160)
Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. (2005) (160)
A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis (2015) (159)
Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept (2005) (158)
Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging. (2003) (156)
Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. (2006) (155)
Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. (2002) (154)
Review: Nonradiographic axial spondyloarthritis: new definition of an old disease? (2013) (153)
Chlamydia pneumoniae--a new causative agent of reactive arthritis and undifferentiated oligoarthritis. (1994) (153)
Oral type II collagen treatment in early rheumatoid arthritis. A double-blind, placebo-controlled, randomized trial. (1996) (147)
Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. (2006) (146)
Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. (2005) (146)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012 (2013) (145)
Persistent clinical efficacy and safety of anti-tumour necrosis factor α therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response (2007) (145)
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial (2019) (141)
Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. (1999) (140)
No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study. (1999) (140)
Pathogenesis of spondylarthropathies (1995) (140)
Six months open label trial of leflunomide in active ankylosing spondylitis (2004) (137)
The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research (2008) (137)
MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group (2019) (134)
Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN) (2014) (132)
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study (2016) (132)
In situ analysis of interleukin-23- and interleukin-12-positive cells in the spine of patients with ankylosing spondylitis. (2013) (131)
ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort (2012) (128)
Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. (2008) (128)
Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study (2007) (128)
Active inflammation and structural change in early active axial spondyloarthritis as detected by whole-body MRI (2012) (126)
Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. (2008) (125)
Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-α therapy and other novel approaches (2002) (124)
The detection of DNA from a range of bacterial species in the joints of patients with a variety of arthritides using a nested, broad-range polymerase chain reaction. (1999) (124)
Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48 (2011) (124)
Diagnosing reactive arthritis: role of clinical setting in the value of serologic and microbiologic assays. (2002) (123)
A single nonamer from the Yersinia 60-kDa heat shock protein is the target of HLA-B27-restricted CTL response in Yersinia-induced reactive arthritis. (1997) (121)
Identification of HLA-B27-Restricted Peptides from the Chlamydia trachomatis Proteome with Possible Relevance to HLA-B27-Associated Diseases1 (2001) (121)
Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis (2006) (120)
Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor alpha antibody infliximab (2005) (120)
Report on the Fourth International Workshop on Reactive Arthritis. (2000) (119)
Comparison of MRI with radiography for detecting structural lesions of the sacroiliac joint using CT as standard of reference: results from the SIMACT study (2017) (119)
Immunology of reactive arthritides. (1995) (118)
A Converse 4-1BB and CD40 Ligand Expression Pattern Delineates Activated Regulatory T Cells (Treg) and Conventional T Cells Enabling Direct Isolation of Alloantigen-Reactive Natural Foxp3+ Treg (2012) (117)
Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial (2012) (117)
T cell cytokine pattern in the joints of patients with Lyme arthritis and its regulation by cytokines and anticytokines. (1997) (117)
Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome. (2011) (116)
Association of genotypes affecting the expression of interleukin-1beta or interleukin-1 receptor antagonist with osteoarthritis. (2000) (115)
HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. (2005) (115)
Evaluation of 2 Screening Strategies for Early Identification of Patients with Axial Spondyloarthritis in Primary Care (2011) (114)
Up regulation of the production of tumour necrosis factor α and interferon γ by T cells in ankylosing spondylitis during treatment with etanercept (2003) (113)
Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? (2013) (113)
Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. (2003) (111)
The burden of non-radiographic axial spondyloarthritis. (2015) (109)
Healthcare and burden of disease in psoriatic arthritis. A comparison with rheumatoid arthritis and ankylosing spondylitis. (2006) (108)
Third International Workshop on Reactive Arthritis. 23-26 September 1995, Berlin, Germany. Report and abstracts. (1996) (107)
Frequency of triggering bacteria in patients with reactive arthritis and undifferentiated oligoarthritis and the relative importance of the tests used for diagnosis (2001) (106)
Referral strategies for early diagnosis of axial spondyloarthritis (2012) (106)
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial (2019) (103)
Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. (2008) (103)
Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: many, but not all patients with sacroiliitis have spondyloarthropathy. (1999) (103)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 (2007) (103)
Axial spondyloarthritis (2015) (102)
Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study (2012) (101)
High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort (2016) (101)
Biological therapies in the spondyloarthritides--the current state. (2004) (101)
New evidence on the management of spondyloarthritis (2016) (100)
Atopic disorders in ankylosing spondylitis and rheumatoid arthritis (2002) (96)
Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis. (2003) (95)
Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis (2011) (93)
Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials (2009) (93)
The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administration's Comments and Concerns (2014) (92)
Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor α, increase of interleukin 10, and predicted by the initial concentration of interleukin 4 (2000) (92)
Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis (2015) (91)
Enthesitis and ankylosis in spondyloarthropathy: What is the target of the immune response? (2000) (90)
Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial (2012) (88)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009 (2009) (87)
Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept. (2004) (87)
Use of dynamic magnetic resonance imaging to detect sacroiliitis in HLA-B27 positive and negative children with juvenile arthritides. (1998) (86)
Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change. (2009) (85)
Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis (2009) (84)
Cytokine-induced human IFN-gamma-secreting effector-memory Th cells in chronic autoimmune inflammation. (2009) (83)
The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta. (1999) (83)
Analysis of the antigen-specific T cell response in reactive arthritis by flow cytometry. (2000) (83)
Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial (2013) (83)
Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis (2010) (81)
Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis (2014) (81)
Autoantibodies against CD74 in spondyloarthritis (2013) (80)
Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. (2019) (80)
Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis (2016) (80)
Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study (2015) (79)
Detailed Analyses of Periarticular Osteoporosis in Rheumatoid Arthritis (2000) (79)
Lack of correlation between the detection of Chlamydia trachomatis DNA in synovial fluid from patients with a range of rheumatic diseases and the presence of an antichlamydial immune response. (1998) (78)
Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. (2007) (77)
Pathogenesis of spondylarthropathies. Persistent bacterial antigen, autoimmunity, or both? (1995) (77)
Infliximab treatment of severe ankylosing spondylitis: one-year followup. (2001) (75)
Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study (2017) (75)
Characterization of the synovial T cell response to various recombinant Yersinia antigens in Yersinia enterocolitica-triggered reactive arthritis. Heat-shock protein 60 drives a major immune response. (1998) (74)
Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort (GESPIC) (2013) (74)
Spinal Inflammation in the Absence of Sacroiliac Joint Inflammation on Magnetic Resonance Imaging in Patients With Active Nonradiographic Axial Spondyloarthritis (2014) (73)
The IL-23–IL-17 pathway as a therapeutic target in axial spondyloarthritis (2019) (72)
Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis (2013) (72)
IL-17A Expression Is Localised to Both Mononuclear and Polymorphonuclear Synovial Cell Infiltrates (2011) (72)
Very early spondyloarthritis: where the inflammation in the sacroiliac joints starts (2005) (71)
Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. (2001) (71)
Recent advances in the pathogenesis of reactive arthritis. (1996) (70)
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008 (2008) (70)
Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. I. Screening of synovial fluid samples of patients with spondyloarthropathies and other arthritides. (1997) (70)
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W) (2019) (70)
Serum Adipokine Levels in Patients With Ankylosing Spondylitis and Their Relationship to Clinical Parameters and Radiographic Spinal Progression (2015) (70)
Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. (2003) (69)
Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA (2017) (68)
Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study (2015) (68)
The frequency of non-radiographic axial spondyloarthritis in relation to symptom duration in patients referred because of chronic back pain: results from the Berlin early spondyloarthritis clinic (2012) (66)
Treatment of active ankylosing spondylitis with pamidronate. (2003) (66)
Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis (2015) (65)
Ankylosing spondylitis (2007) (65)
The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. (2011) (64)
Analysis of cytokine profiles in synovial T cell clones from chlamydial reactive arthritis patients: predominance of the Th1 subset (1993) (64)
Etanercept in the Longterm Treatment of Patients With Ankylosing Spondylitis (2009) (64)
Similarities and differences between nonradiographic and radiographic axial spondyloarthritis: a clinical, epidemiological and therapeutic assessment (2014) (64)
Impact of anti-tumour necrosis factor α treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis (2004) (63)
Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment (2008) (63)
Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2 (2017) (61)
Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2 (2013) (61)
Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study (2018) (61)
Pathogenetic role of Chlamydia, Yersinia and Borrelia in undifferentiated oligoarthritis. (1992) (61)
Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis (2016) (60)
Current perspectives in reactive arthritis. (1993) (59)
T cells are responsible for the enhanced synovial cellular immune response to triggering antigen in reactive arthritis (1993) (59)
An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis (2006) (57)
Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial (2015) (56)
Developments in the scientific and clinical understanding of the spondyloarthritides (2009) (56)
Anti-tumour necrosis factor α therapy for ankylosing spondylitis: international experience (2002) (56)
Nested polymerase chain reaction strategy simultaneously targeting DNA sequences of multiple bacterial species in inflammatory joint diseases. II. Examination of sacroiliac and knee joint biopsies of patients with spondyloarthropathies and other arthritides. (1997) (56)
Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis (2005) (55)
Improved detection of erosions in the sacroiliac joints on MRI with volumetric interpolated breath-hold examination (VIBE): results from the SIMACT study (2018) (55)
Kaposi's Sarcoma-Associated Herpesvirus Cytotoxic T Lymphocytes Recognize and Target Darwinian Positively Selected Autologous K1 Epitopes (2003) (54)
The place of juvenile onset spondyloarthropathies in the Durban 1997 ILAR classification criteria of juvenile idiopathic arthritis. International League of Associations for Rheumatology. (2002) (54)
Whole-body MRI as a new screening tool for detecting axial and peripheral manifestations of spondyloarthritis (2007) (54)
Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. (2010) (53)
Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years (2013) (53)
Low incidence of reactive arthritis in children following a salmonella outbreak (2001) (53)
Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis (2019) (52)
Magnetic Resonance Imaging Compared to Conventional Radiographs for Detection of Chronic Structural Changes in Sacroiliac Joints in Axial Spondyloarthritis (2013) (52)
Therapy of ankylosing spondylitis. Part II: Biological therapies in the spondyloarthritides (2005) (52)
Developments in therapies for spondyloarthritis (2012) (52)
miR-148a is upregulated by Twist1 and T-bet and promotes Th1-cell survival by regulating the proapoptotic gene Bim (2015) (50)
Role of whole-body magnetic resonance imaging in diagnosing early spondyloarthritis. (2009) (50)
Diverse effects of infliximab and etanercept on T lymphocytes. (2005) (50)
Synovial and Peripheral Blood CD4+FoxP3+ T Cells in Spondyloarthritis (2011) (50)
Radiographic progression in ankylosing spondylitis/axial spondyloarthritis: how fast and how clinically meaningful? (2012) (50)
Mechanism of New Bone Formation in Axial Spondyloarthritis (2017) (49)
Multispecific CD4+ T Cell Response to a Single 12-mer Epitope of the Immunodominant Heat-Shock Protein 60 of Yersinia enterocolitica in Yersinia-Triggered Reactive Arthritis: Overlap with the B27-Restricted CD8 Epitope, Functional Properties, and Epitope Presentation by Multiple DR Alleles1 (2000) (49)
Histomorphologic and Histomorphometric Characteristics of Zygapophyseal Joint Remodeling in Ankylosing Spondylitis (2014) (49)
Treatment of spondyloarthropathies with antibodies against tumour necrosis factor α: first clinical and laboratory experiences (2000) (49)
Easy assessment of axial spondyloarthritis (early ankylosing spondylitis) at the bedside (2006) (49)
Analysis of the CD8+ T cell response to the G1 domain of aggrecan in ankylosing spondylitis (2004) (48)
One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare (2012) (48)
Long-term efficacy of adalimumab after drug withdrawal and retreatment in patients with active non-radiographically evident axial spondyloarthritis who experience a flare. (2013) (47)
Use of contrast enhanced magnetic resonance imaging to detect spinal inflammation in patients with spondyloarthritides. (2002) (46)
Staging of patients with ankylosing spondylitis: a preliminary proposal (2002) (46)
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019 (2019) (46)
Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists (2007) (45)
Anti-TNFα: a new dimension in the pharmacotherapy of the spondyloarthropathies !? (2000) (44)
Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab (2014) (44)
Biologic therapies in the spondyloarthritis: new opportunities, new challenges (2003) (43)
Loss of methylation at the IFNG promoter and CNS‐1 is associated with the development of functional IFN‐γ memory in human CD4+ T lymphocytes (2013) (43)
The possible role of myocardial biopsy in systemic sclerosis. (2000) (43)
Classification and Diagnosis of Axial Spondyloarthritis — What Is the Clinically Relevant Difference? (2015) (42)
Serum levels of leptin and high molecular weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial (2017) (42)
Immunohistochemical Analysis of Osteoblasts in Zygapophyseal Joints of Patients with Ankylosing Spondylitis Reveal Repair Mechanisms Similar to Osteoarthritis (2010) (42)
Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study (2021) (41)
Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment. (2002) (41)
Aetiological role of bacteria associated with reactive arthritis in pauciarticular juvenile chronic arthritis. (1992) (41)
Determinants of psychological well-being in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data (2018) (41)
The unmet need in rheumatology: Reports from the targeted therapies meeting 2017. (2017) (41)
Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort (2017) (40)
Use of HLA-B27 tetramers to identify low-frequency antigen-specific T cells in Chlamydia-triggered reactive arthritis (2004) (39)
Building consensus on nomenclature and disease classification for ankylosing spondylitis: results and discussion of a questionnaire prepared for the International Workshop on New Treatment Strategies in Ankylosing Spondylitis, Berlin, Germany, 18–19 January 2002 (2002) (39)
Identification of Novel Human Aggrecan T Cell Epitopes in HLA-B27 Transgenic Mice Associated with Spondyloarthropathy1 (2004) (38)
The Evolutionarily Conserved Ribosomal Protein L23 and the Cationic Urease β-Subunit of Yersinia enterocolitica O:3 Belong to the Immunodominant Antigens in Yersinia-Triggered Reactive Arthritis: Implications for Autoimmunity (1994) (38)
OP0169 Sarilumab for the treatment of ankylosing spondylitis: Results of a phase 2, randomized. Double-blind, placebo-controlled, international study (align) (2013) (38)
How early should ankylosing spondylitis be treated with tumour necrosis factor blockers? (2005) (37)
Functional relevance of radiographic spinal progression in axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort (2018) (37)
An elevated level of IL-10- and TGFβ-secreting T cells, B cells and macrophages in the synovial membrane of patients with reactive arthritis compared to rheumatoid arthritis (2004) (37)
Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care (2018) (37)
Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study (2019) (37)
Course of Magnetic Resonance Imaging–Detected Inflammation and Structural Lesions in the Sacroiliac Joints of Patients in the Randomized, Double‐Blind, Placebo‐Controlled Danish Multicenter Study of Adalimumab in Spondyloarthritis, as Assessed by the Berlin and Spondyloarthritis Research Consortium (2016) (37)
Granulation Tissue Eroding the Subchondral Bone Also Promotes New Bone Formation in Ankylosing Spondylitis (2016) (36)
Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases (2003) (35)
Clinical and imaging characteristics of osteitis condensans ilii as compared with axial spondyloarthritis. (2020) (35)
Pathogenesis of reactive arthritis (2001) (35)
Sensitivity and discriminatory ability of the Ankylosing Spondylitis Disease Activity Score in patients treated with etanercept or sulphasalazine in the ASCEND trial. (2012) (35)
Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-α Inhibitors for Up to 10 Years (2016) (35)
New treatment options in ankylosing spondylitis: a role for anti-TNFα therapy (2001) (34)
Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience. (2002) (34)
Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritis--3-Year data of the ESTHER trial. (2016) (34)
Whole-body magnetic resonance imaging evaluation of widespread inflammatory lesions in a patient with ankylosing spondylitis before and after 1 year of treatment with infliximab. (2007) (34)
How to define remission in ankylosing spondylitis? (2012) (34)
What is the best treatment target in axial spondyloarthritis: tumour necrosis factor &agr;, interleukin 17, or both? (2018) (34)
Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations (2008) (34)
Definition of disease duration in ankylosing spondylitis: reassessing the concept (2006) (33)
Age- and Sex-dependent Frequency of Fat Metaplasia and Other Structural Changes of the Sacroiliac Joints in Patients without Axial Spondyloarthritis: A Retrospective, Cross-sectional MRI Study (2018) (33)
The 19 kDa protein of Yersinia enterocolitica O:3 is recognized on the cellular and humoral level by patients with Yersinia induced reactive arthritis. (1999) (32)
From transcriptome to cytome: Integrating cytometric profiling, multivariate cluster, and prediction analyses for a phenotypical classification of inflammatory diseases (2008) (32)
Problems and advances in the diagnosis of reactive arthritis. (1999) (31)
Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort (2015) (31)
In vivo pre-activation of monocytes in patients with axial spondyloarthritis (2015) (31)
Non-radiographic axial spondyloarthritis patients without initial evidence of inflammation may develop objective inflammation over time (2017) (31)
Oral collagen in the treatment of rheumatoid arthritis. (1998) (31)
Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers (2014) (31)
Consistently Good Clinical Response in Patients with Early Axial Spondyloarthritis After 3 Years of Continuous Treatment with Etanercept: Longterm Data of the ESTHER Trial (2014) (31)
Limited Diagnostic Value of Unilateral Sacroiliitis in Scintigraphy in Assessing Axial Spondyloarthritis (2010) (30)
Recognition of chlamydial antigen by HLA-B27-restricted cytotoxic T cells in HLA-B*2705 transgenic CBA (H-2k) mice. (1997) (30)
Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison (2019) (30)
Results of a multicenter placebo-controlled double-blind randomized phase III clinical study of treatment of rheumatoid arthritis with recombinant interferon-gamma (2004) (30)
Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab (2017) (30)
Regulation of Expression of Cytokines and Growth Factors in Osteoarthritic Cartilage Explants (2001) (29)
Erosions and Fatty Lesions of Sacroiliac Joints in Patients with Axial Spondyloarthritis: Evaluation of Different MRI Techniques and Two Scoring Methods (2014) (29)
Early diagnosis of spondyloarthritis (2006) (29)
Comparison of an online self-referral tool with a physician-based referral strategy for early recognition of patients with a high probability of axial spa. (2020) (28)
Relationship of bone mineral density with disease activity and functional ability in patients with ankylosing spondylitis: a cross-sectional study (2011) (28)
Sensitivity and Specificity of Autoantibodies Against CD74 in Nonradiographic Axial Spondyloarthritis (2019) (28)
[Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany]. (2003) (27)
Cartilage in facet joints of patients with ankylosing spondylitis (AS) shows signs of cartilage degeneration rather than chondrocyte hypertrophy: implications for joint remodeling in AS (2015) (27)
Genetic diagnostic profiling in axial spondyloarthritis: a real world study. (2017) (27)
Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial (2018) (27)
Association of HLA-DRB1*02 with osteoarthritis in a cohort of 106 patients. (2002) (27)
Identification of HLA-B27-restricted peptides in reactive arthritis and other spondyloarthropathies: computer algorithms and fluorescent activated cell sorting analysis as tools for hunting of HLA-B27-restricted chlamydial and autologous crossreactive peptides involved in reactive arthritis and anky (2003) (26)
Can structural damage be prevented in ankylosing spondylitis? (2009) (26)
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018 (2019) (26)
Spondyloarthritis at the crossroads of imaging, pathology, and structural damage in the era of biologics (2008) (25)
OP0166 Tocilizumab (TCZ) is not effective for the treatment of ankylosing spondylitis (AS): Results of a phase 2, international, multicentre, randomised, double-blind, placebo-controlled trial (2013) (25)
Treatment of reactive arthritis with antibiotics. (1998) (25)
Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52‐week pooled results from two phase 3 studies (2017) (25)
Five-year follow-up of radiographic sacroiliitis: progression as well as improvement? (2015) (25)
Impact of baseline C-reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3-year pooled data from two phase III studies (2018) (25)
Disease mechanisms in reactive arthritis (2004) (24)
Inflammation and repair mechanisms. (2009) (24)
Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis. (2019) (24)
HLA-B27-restricted antigen presentation by human chondrocytes to CD8+ T cells: potential contribution to local immunopathologic processes in ankylosing spondylitis. (2009) (24)
Predictors of remission in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab in the ABILITY-3 study (2019) (24)
Development of a core set of domains for data collection in cohorts of patients with ankylosing spondylitis receiving anti-tumor necrosis factor-alpha therapy. (2008) (24)
Aetiological agents and immune mechanisms in enterogenic reactive arthritis. (1996) (23)
Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials (2007) (23)
[Revision of the recommendations of the Commission on Pharmacotherapy of the German society for Rheumatology. Therapy with tumour necrosis factor blockers for inflammatory rheumatic illnesses]. (2007) (23)
Comparison of Clinical Examination versus Whole-body Magnetic Resonance Imaging of Enthesitis in Patients with Early Axial Spondyloarthritis during 3 Years of Continuous Etanercept Treatment (2016) (23)
New treatment targets for axial spondyloarthritis. (2016) (23)
How important is early therapy in axial spondyloarthritis? (2012) (23)
Data-Driven Definitions for Active and Structural MRI Lesions in the Sacroiliac Joint in Spondyloarthritis and their Predictive Utility. (2021) (23)
Course of patients with juvenile spondyloarthritis during 4 years of observation, juvenile part of GESPIC (2017) (22)
Systematic review of clinical, humanistic, and economic outcome comparisons between radiographic and non-radiographic axial spondyloarthritis. (2017) (22)
Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial. (2015) (22)
Peripheral spondyloarthritis: Concept, diagnosis and treatment. (2018) (22)
Referral Patterns, Diagnosis, and Disease Management of Patients With Axial Spondyloarthritis (2014) (22)
Impaired Peripheral Th1 CD4+ T Cell Response to Escherichia coli Proteins in Patients with Crohn’s Disease and Ankylosing Spondylitis (2011) (22)
Membrane glucocorticoid receptor expression on peripheral blood mononuclear cells in patients with ankylosing spondylitis. (2006) (22)
Progression of Structural Damage in the Sacroiliac Joints in Patients With Early Axial Spondyloarthritis During Long‐Term Anti–Tumor Necrosis Factor Treatment: Six‐Year Results of Continuous Treatment With Etanercept (2019) (22)
Effects of Long‐Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104‐Week Results From a Randomized, Placebo‐Controlled Study (2017) (22)
[Recommendations for the management of ankylosing spodylitis after ASAS/EULAR. Evaluation in the German language area]. (2006) (22)
Increased frequency of Sjögren's syndrome in patients with spondyloarthropathy. (1998) (21)
Cost-effectiveness of etanercept in patients with severe ankylosing spondylitis in Germany. (2010) (21)
Interleukin-17A Blockade with Secukinumab Reduces Spinal Inflammation in Patients with Ankylosing Spondylitis As Early As Week 6, As Detected by Magnetic Resonance Imaging (2011) (21)
Sweet's syndrome in a patient with acute Crohn's colitis and longstanding ankylosing spondylitis. (1999) (21)
Diagnosing early ankylosing spondylitis (2007) (21)
Classification, diagnosis, and referral of patients with axial spondyloarthritis. (2012) (21)
Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort (2018) (21)
A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis (2016) (20)
Visceral Leishmaniasis mimicking a flare of systemic lupus erythematosus (1991) (20)
Rheumatologic manifestations of gastrointestinal disorders. (1999) (20)
Differential synovial Th1 cell reactivity towards Escherichia coli antigens in patients with ankylosing spondylitis and rheumatoid arthritis (2012) (20)
Relation of HLA-B27, Tumor Necrosis Factor-α Promoter Gene Polymorphisms, and T Cell Cytokine Production in Ankylosing Spondylitis — A Comprehensive Genotype-Phenotype Analysis from an Observational Cohort (2011) (20)
Can unresolved infection precipitate autoimmune disease? (2006) (19)
The possible role of Shigella in sporadic enteric reactive arthritis. (1993) (19)
Deep learning for detection of radiographic sacroiliitis: achieving expert-level performance (2021) (19)
Adalimumab for the treatment of ankylosing spondylitis (2007) (19)
Vertebral Erosions Associated with Spinal Inflammation in Patients with Ankylosing Spondylitis Identified by Magnetic Resonance Imaging: Changes After 2 Years of Tumor Necrosis Factor Inhibitor Therapy (2013) (18)
Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once HLA-B27 status is known? (2019) (18)
What is the most important outcome parameter in ankylosing spondylitis? (2008) (18)
[Long version on the S3 guidelines for axial spondyloarthritis including Bechterew's disease and early forms, Update 2019 : Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies and other organizations]. (2019) (18)
Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker? (2010) (18)
Use of methotrexate in patients with ankylosing spondylitis. (2010) (18)
Synovial cell production of IL-26 induces bone mineralization in spondyloarthritis (2017) (18)
Workshop report: clinical diagnosis and imaging of sacroiliitis, Innsbruck, Austria, October 9, 2003. (2004) (17)
Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice. (2008) (17)
[Glucocorticoid-induced osteoporosis]. (2001) (17)
Treatment of rheumatoid arthritis and ankylosing spondylitis. (2009) (17)
ASAS recommendations for variables to be collected in clinical trials/epidemiological studies of spondyloarthritis (2012) (16)
The risks of smoking in patients with spondyloarthritides (2012) (16)
Infliximab in the treatment of active and severe ankylosing spondylitis. (2002) (16)
Withdrawal of biologic therapy in axial spondyloarthritis: the experience in established disease. (2013) (16)
The Solvent-Inaccessible Cys67 Residue of HLA-B27 Contributes to T Cell Recognition of HLA-B27/Peptide Complexes1 (2004) (16)
Inflammation, new bone formation and treatment options in axial spondyloarthritis (2014) (16)
Treatment of Axial Spondyloarthritis: What Does the Future Hold? (2020) (16)
Role of Novel Biological Therapies in Psoriatic Arthritis (2012) (15)
[Inception cohorts for spondyloarthropathies]. (2000) (15)
Overexpanded B cell clone mediating leukemic arthritis by abundant secretion of interleukin-1beta: a case report. (1998) (15)
5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial (2020) (15)
Upadacitinib in Active Ankylosing Spondylitis: 1-Year Results From the Double-Blind, Placebo-Controlled SELECT-AXIS 1 Study and Open-Label Extension. (2021) (15)
[Evidence-based recommendations on diagnostics and therapy of axial spondyloarthritis : S3 guidelines of the German Society of Rheumatology (DGRh) in cooperation with the Association of the Scientific Medical Societies in Germany (AWMF)]. (2016) (15)
Burden of illness associated with non-radiographic axial spondyloarthritis: a multiperspective European cross-sectional observational study. (2016) (14)
THU0272 Efficacy of oral prednisolone in active ankylosing spondylitis – results of a double blind placebo controlled trial (2013) (14)
[ASAS/EULAR recommendations for the management of ankylosing spondylitis : evaluation of the 2010 update in the German-speaking area]. (2013) (14)
OP0155 Ustekinumab Effectively Reduces Active Inflammation as Detected by Magnetic Resonance Imaging in Patients with Active Ankylosing Spondylitis: Results of A 28-Week, Prospective, Open-Label, Proof-Of-Concept Study (TOPAS) (2014) (14)
How to screen for axial spondyloarthritis in primary care? (2012) (14)
Bacteria-specific lymphocyte proliferation in peripheral blood in reactive arthritis and related diseases. (1998) (13)
Remission and possible discontinuation of biological therapy in axial spondyloarthritis. (2013) (13)
[Diagnosis and early diagnosis of ankylosing spondylitis]. (2004) (13)
Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease. (2013) (13)
Detection of Sacroiliitis by Short-tau Inversion Recovery and T2-weighted Turbo Spin Echo Sequences: Results from the SIMACT Study (2019) (13)
OP0108 Clinical and Imaging Efficacy of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial (2013) (13)
Anti-TNF agents for the treatment of spondyloarthropathies (2002) (13)
Do ethnicity, degree of family relationship, and the spondyloarthritis subtype in affected relatives influence the association between a positive family history for spondyloarthritis and HLA-B27 carriership? Results from the worldwide ASAS cohort (2018) (13)
Anti-TNFalpha: a new dimension in the pharmacotherapy of the spondyloarthropathies !? (2000) (13)
Three-colour flowcytometric examination of CD4/CD45 subsets reveals no differences in peripheral blood and synovial fluid between patients with reactive arthritis and rheumatoid arthritis. (1994) (12)
Fluoroscopy-guided application of corticosteroids for local control of manubriosternal joint pain in patients with spondyloarthropathies (2004) (12)
THU0233 Secukinumab Reduces Sacroiliac Joint and Spinal Inflammation in Patients with Ankylosing Spondylitis: MRI Data from a Phase 3 Randomized, Double-Blind, Placebo-Controlled Study (MEASURE 1) (2015) (12)
Course of active inflammatory and fatty lesions in patients with early axial spondyloarthritis treated with infliximab plus naproxen as compared to naproxen alone: Results from the INFAST study (2016) (12)
Documentation of off-label use of biologics in Rheumatoid Arthritis (2013) (12)
Investigation of involved tissue in axial spondyloarthritis--what have we learnt from immunohistochemical studies? (2010) (12)
Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics. (2016) (12)
OP0001 Effect of Secukinumab, An Interleukin-17a Inhibitor, on Spinal Radiographic Changes through 2 Years in Patients with Active Ankylosing Spondylitis: Results of The Phase 3 Study, Measure 1 (2016) (12)
[Quantitatively evaluated dynamic magnetic resonance tomography in chronic polyarthritis of the knee joint. A therapeutic follow-up after intra-articular cortisone application]. (1992) (12)
Homologous high-throughput expression and purification of highly conserved E coli proteins (2007) (12)
Efficacy and Safety of Adalimumab in Patients with Non-Radiographic Axial Spondyloarthritis - Results From a Phase 3 Study (2011) (12)
A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: non-steroidal anti-inflammatory drugs. (2009) (12)
Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) (2021) (12)
Longitudinal investigation of bacterium-specific synovial lymphocyte proliferation in reactive arthritis and lyme arthritis. (1998) (11)
THU0400 CLINICAL COURSE OF EARLY AXIAL SPONDYLOARTHRITIS OVER TEN YEARS: LONG-TERM RESULTS FROM THE GERMAN SPONDYLOARTHRITIS INCEPTION COHORT (2020) (11)
Performance of the Ankylosing Spondylitis Disease Activity Score based on a quick quantitative C-reactive protein assay in patients with axial spondyloarthritis. (2019) (11)
Blockade of intra-articular adrenergic receptors increases analgesic demands for pain relief after knee surgery (2011) (11)
Treatment with adalimumab reduces signs and symptoms and induces partial remission in patients with ankylosing spondylitis (AS): 1-year results from ATLAS. (2006) (11)
An explorative study on deep profiling of peripheral leukocytes to identify predictors for responsiveness to anti-tumour necrosis factor alpha therapies in ankylosing spondylitis: natural killer cells in focus (2018) (11)
Description of spinal MRI lesions and definition of a positive MRI of the spine in axial SpA (2010) (11)
The prevalence and impact of comorbidities on patients with axial spondyloarthritis: results from a nationwide population-based study (2020) (11)
THU0275 Sustained efficacy of adalimumab in patients with non-radiographic axial spondyloarthritis: Week 68 results from ability 1 (2013) (11)
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial (2022) (10)
Current Controversies in Spondyloarthritis: SPARTAN (2010) (10)
Current Unmet Needs in Spondyloarthritis (2019) (10)
Central reader evaluation of MRI scans of the sacroiliac joints from the ASAS classification cohort: discrepancies with local readers and impact on the performance of the ASAS criteria (2020) (10)
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures]. (2014) (10)
Ef fi cacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis : 24-week results of a double-blind randomised placebo-controlled Phase 3 study (2013) (10)
OP0168 Secukinumab Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: 52-Week Data from Measure 2, A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing (2015) (10)
Spondylitis ankylosans (2009) (10)
Co-occurrence of spondyloarthropathy and connective tissue disease: development of Sjögren's syndrome and mixed connective tissue disease (MCTD) in a patient with ankylosing spondylitis. (2002) (9)
IgA antibodies against CD74 are associated with structural damage in the axial skeleton in patients with axial spondyloarthritis. (2020) (9)
Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab (2005) (9)
[Measurement of quality of life in patients with active ankylosing spondylitis being treated with infliximab-a comparison of SF-36 and SF-12]. (2004) (9)
Treatment of Reactive Arthritis (2012) (9)
ASessment in Ankylosing Spondylitis (ASAS) international working group: a model for psoriatic arthritis and psoriasis? (2005) (9)
Challenges of diagnosis and management of axial spondyloarthritis in North Africa and the Middle East: An expert consensus (2016) (9)
In situ analysis of interleukin-6 expression at different sites of zygapophyseal joints from patients with ankylosing spondylitis in comparison to controls (2015) (9)
Identification of immunodominant CD4+ T cell epitopes in patients with Yersinia-induced reactive arthritis by cytometric cytokine secretion assay. (2006) (9)
Widespread vasculopathy with hemolytic uremic syndrome, perimyocarditis and cystic pancreatitis in a young woman with mixed connective tissue disease (1993) (9)
The specific antibacterial proliferation of reactive arthritis synovial T cells is not due to their higher proportion of CD45RO+ cells compared to peripheral blood. (1994) (9)
Relevance of osteoproliferation as an outcome parameter in ankylosing spondylitis (2008) (9)
Psoriatische Onycho-Pachydermo- Periostitis (POPP) (1997) (9)
Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension (2021) (9)
The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study (2020) (9)
New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy. (2001) (9)
Identification of the predominant antigenic epitopes in intestinal flora in IBD (2008) (8)
Immunological basis of oral tolerance. (1995) (8)
THU0274 Double-blind, placebo-controlled, 28-week trial of efficacy and safety of infliximab plus naproxen vs naproxen alone in patients with early, active axial spondyloarthritis treated with a submaximal dose of NSAIDS: Preliminary results of INFAST part I (2013) (8)
THU0238 A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Subcutaneous Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis (2015) (8)
[Dynamic magnetic resonance imaging in the differentiation of inflammatory joint lesions]. (1990) (8)
Severe lupus crisis with agranulocytosis and anuric renal failure due to a mesangial lesion (WHO IIB)--successful treatment with cyclophosphamide pulse followed by plasmapheresis. (1991) (8)
Spondyloarthropathies in 2010: New insights into therapy—TNF blockade and beyond (2011) (8)
[ASAS recommendations on the use of TNF inhibitors for patients with axial spondyloarthritis : evaluation of the 2010 update in the German-speaking area]. (2013) (8)
EVALUATION OF EFFICACY AND SAFETY OF SECUKINUMAB IN THE TREATMENT OF PATIENTS WITH MODERATE-TO-SEVERE ANKYLOSING SPONDYLITIS (2012) (8)
Correction: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab (2005) (7)
Reactive Spondyloarthritis: Epidemiology, Clinical Features, and Treatment (2006) (7)
Clinician’s Manual on Axial Spondyloarthritis (2014) (7)
Classification criteria for rheumatoid arthritis and ankylosing spondylitis. (2009) (7)
[Sapho syndrome: 2 case reports]. (1995) (7)
The value of specific antibody detection and culture in the diagnosis of reactive arthritis (1993) (7)
New treatment strategies in ankylosing spondylitis: Proceedings of the Ankylosing Spondylitis Workshop, Berlin, Germany, 18–19 January 2002 (2002) (7)
T cell response to human HSP60 and yersinia 19 kDa in ankylosing spondylitis and rheumatoid arthritis: no evidence for a causal role of these antigens in the pathogenesis (2002) (7)
FRI0127 Eular Recommendations for the Use of Imaging in Spondyloarthritis in Clinical Practice (2014) (7)
A systematic comparison between rheumatoid arthritis and ankylosing spondylitis: an introduction. (2009) (6)
Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension (2022) (6)
Long Term Inhibition of Interleukin (IL)-17A with Secukinumab Improves Clinical Symptoms and Reduces Spinal Inflammation As Assessed by Magnetic Resonance Imaging in Patients with Ankylosing Spondylitis. (2012) (6)
CHARACTERIZATION OF THE SYNOVIAL T CELL RESPONSE TO VARIOUS RECOMBINANT YERSINH ANTIGENS IN YERSINIA ENTEROCOLITICA-TRIGGERED REACTIVE ARTHRITIS (1998) (6)
Type II collagen serology: a guide to clinical responsiveness to oral tolerance? (2005) (6)
The safety of celecoxib in ankylosing spondylitis treatment. (2008) (6)
Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safety. (2016) (6)
Alteration in T Cell/Macrophage Ratio may Reveal Lymphocyte Proliferation Specific for the Triggering Antigen in Reactive Arthritis (1992) (6)
[Diagnosis and treatment of ankylosing spondylitis (Bechterew disease)]. (2005) (6)
Prevalence and molecular diversity of pHS-2 plasmids, marker for arthritogenicity, among clinical Escherichia coli Shigella isolates. (2003) (6)
[Early axial spondyloarthritis. Diagnostic approach and screening]. (2012) (6)
GOLIMUMAB, A NEW HUMAN TNF-alpha ANTIBODY ADMINISTERED SUBCUTANEOUSLY EVERY 4 WEEKS, IN ANKYLOSING SPONDYLITIS : 104-WEEK EFFICACY AND SAFETY RESULTS OF THE RANDOMIZED, PLACEBO-CONTROLLED GO-RAISE STUDY (2010) (6)
OP0110 Treat-To-Target Recommendations for Spondyloarthritis, Including Ankylosing Spondylitis and Psoriatic Arthritis: A Consensus of an International Task Force (2013) (6)
Treatment of reactive arthritis: a practical guide. (2000) (6)
Infliximab therapy for patients with ankylosing spondylitis: on-demand or continuous treatment? (2008) (6)
THU0358 Constant Clinical Response in Patients with Early Axial Spondyloarthritis after Continuous Treatment with Etanercept - 4 Year Data of the Esther Trial (2013) (5)
FRI0420 Long term inhibition of IL-17a with secukinumab reduces spinal inflammation but has no influence on fatty lesions as assessed by magnetic resonance imaging in patients with ankylosing spondylitis (2013) (5)
Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-term efficacy and safety in AS (ATLAS) (2008) (5)
Editorial: Inflammatory Back Pain and Axial Spondyloarthritis: Lessons for Clinical Practice and Epidemiologic Research (2018) (5)
SAT0347 COMORBID CONDITIONS ARE ASSOCIATED WITH HIGHER DISEASE ACTIVITY AND WORSE FUNCTIONAL STATUS IN AXIAL SPONDYLOARTHRITIS: A POPULATION-BASED ANALYSIS OF INSURANCE CLAIMS LINKED TO PATIENT SURVEY DATA (2019) (5)
[Magnetic resonance tomography of finger polyarthritis: morphology and cartilage signals after ademetionine therapy]. (1995) (5)
[Abdominal actinomycosis after stomach surgery in a patient with long-term rheumatoid arthritis treated with methotrexate]. (1999) (5)
THU0359 Secukinumab demonstrates consistent safety over long-term exposure (up to 3 years) in patients with active ankylosing spondylitis: pooled analysis of three phase 3 trials (2017) (5)
Spinal inflammation in the absence of SI joint inflammation on MRI in patients with active non-radiographic axial spondyloarthritis (2012) (5)
Disease activity in ankylosing spondylitis: the global therapeutic target (2017) (5)
Effective treatment of early rheumatoid arthritis with a combination of methotrexate, prednisolone and cyclosporin. (2002) (5)
OP0145 Continuous Versus on Demand Treatment of Ankylosing Spondylitis with Diclofenac Over 2 Years Does not Prevent Radiographic Progression of the Spine – Results from a Randomized Prospective Multi-Center Trial (Enradas) (2015) (5)
Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial (2021) (5)
Definition of discontinuation of anti-tumour necrosis factor therapy in rheumatoid arthritis: a preliminary proposal (2003) (5)
Treatment Challenges in Axial Spondylarthritis and Future Directions (2013) (5)
MRI lesions of the spine in patients with axial spondyloarthritis: an update of lesion definitions and validation by the ASAS MRI working group (2022) (5)
Cytokines and the immunopathology of the spondyloarthropathies (1999) (5)
Clinical response to the anti-tumor necrosis factor alpha antibody infliximab in patients with ankylosing spondylitis over 3 years (2005) (5)
THU0071 Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Demonstrate the Same Clinical Disease Course over Two Years: Results from the GESPIC Cohort (2014) (5)
OP0106 Effect of Certolizumab Pegol on Signs and Symptoms of Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 24-Week Results of Rapid-Axspa Study (2013) (5)
AB0743 Secukinumab Improves Multiple Parameters of Disease Activity in Subjects with Active Ankylosing Spondylitis Through 52 Weeks of Subcutaneous Therapy: Data From the Phase 3 Measure 2 Study (2015) (4)
Treatment With Tumor Necrosis Factor Inhibitors Is Associated With a Time‐Shifted Retardation of Radiographic Sacroiliitis Progression in Patients With Axial Spondyloarthritis: 10‐Year Results From the German Spondyloarthritis Inception Cohort (2022) (4)
Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2 (2018) (4)
[Reactive arthritis associated bacteria as the etiology of undifferentiated oligoarthritis]. (1993) (4)
Peripheral blood mononuclear cells of patients with reactive arthritis secrete more IL-10 and less TNF-α than patients with lyme arthritis and rheumatoid arthritis (1997) (4)
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 3 Clinical symptoms]. (2014) (4)
[Health care and disease burden in persons with axial spondyloarthritis in Germany]. (2019) (4)
Infliximab for the treatment of ankylosing spondylitis (2005) (4)
Diagnostic delay in axial spondyloarthritis – a past or current problem? (2021) (4)
Synovial T cell proliferation to the Yersinia enterocolitica 19 kDa antigen differentiates yersinia triggered reactive arthritis (ReA) from ReA triggered by other enterobacteria (2002) (4)
AB0660 LONG-TERM CLINICAL OUTCOME OF ANTI-TNF TREATMENT IN PATIENTS WITH EARLY AXIAL SPONDYLOARTHRITIS: 10-YEAR DATA OF THE ETANERCEPT VS. SULFASALAZIN IN EARLY AXIAL SPONDYLOARTHRITIS TRIAL (2020) (4)
Reactive arthritis. (1999) (4)
[Cost of illness in axial spondylarthritis for patients with and without tumor necrosis factor inhibitor treatment: results of a routine data analysis]. (2019) (4)
The safety of celecoxib in ankylosing spondylitis treatment (2008) (4)
[Is it possible to delegate medical services to qualified nurses specialized in rheumatology when evaluating patients with suspicion of ankylosing spondylitis?-Results of the PredAS study]. (2020) (4)
[Costosternal swelling and diffuse bone pain in tubercular osteomyelitis]. (1997) (4)
SAT0259 Low rate of spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison (2018) (4)
[Therapy of ankylosing spondylitis (AS) with radium chloride (224SpondylAT)]. (2001) (4)
THU0210 Secukinumab Efficacy in Anti-Tnf-Naive Patients and Patients Previously Exposed to Anti-Tnf Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (Measure 2) in Active Ankylosing Spondylitis (2015) (4)
[Ankylosing spondylitis. Target treatment criteria]. (2009) (4)
LONG TERM EFFICACY AND SAFETY OF ETANERCEPT IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 148 TO 160 WEEK ANALYSIS FROM AN ONGOING EU TRIAL: 215 (2006) (4)
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 4 Classification and diagnostic criteria]. (2014) (4)
Republished: The risks of smoking in patients with spondyloarthritides (2012) (4)
AB0736 Secukinumab Significantly Improves Physical Function, Quality of Life, and Work Productivity Through 52 Weeks in Subjects with Active Ankylosing Spondylitis in the Phase 3 Measure 2 Study (2015) (4)
[Pathogenesis of spondylarthritis : Relevance for treatment]. (2020) (4)
[Therapy with oral type II collagen as a new possibility of selective immunosuppression in therapy of rheumatoid arthritis]. (1994) (4)
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8 Therapy, 8.1 Treatment concept, 8.2 Therapy targets and strategy]. (2014) (4)
CD27+ memory and CD27- effector CD8+ T cells are responsible for a decreased production of proinflammatory cytokines in HLA B27-positive subjects. (2005) (4)
Management of ankylosing spondylitis (2011) (4)
Ankylosing spondylitis self-help organisations - do members differ from non-members? (2016) (4)
Second International Workshop on Reactive Arthritis. (1993) (4)
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 1 Introduction/preliminary comments]. (2014) (4)
[Development of morbidity and mortality in patients with spondyloarthritis]. (2011) (4)
Relationship Between MRI and Clinical Remission In Patients With Non-Radiographic Axial Spondyloarthritis After Two Years Of Adalimumab Therapy (2013) (4)
Spondyloarthritis and Chronic Idiopathic Arthropathies (2006) (4)
What amount of structural damage defines sacroiliitis: a CT study (2022) (4)
Commented glossary for rheumatic spinal diseases. (1996) (4)
THU0361 Relationship between MRI and Clinical Remission in Patients with Non-Radiographic Axial Spondyloarthritis after Two Years of Adalimumab Therapy (2013) (3)
Characteristics of patients with axial spondyloarthritis by geographic regions: PROOF multicountry observational study baseline results (2021) (3)
[Synovial cellular immune response to bacterial pathogens in patients with chronic juvenile arthritis]. (1993) (3)
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 6 Diagnostics]. (2014) (3)
SAT0337 Clinical Response and Remission in Patients with Non-Radiographic Axial Spondyloarthritis after Three Years of Adalimumab Therapy (2014) (3)
[Ankylosing spondylitis--current state of imaging including scoring methods]. (2006) (3)
Comparing MRI and conventional radiography for the detection of structural changes indicative of axial spondyloarthritis in the ASAS cohort. (2022) (3)
THU0375 IMPROVEMENTS IN GLOBAL FUNCTIONING AND HEALTH-RELATED QUALITY OF LIFE AND THEIR ASSOCIATION WITH DISEASE ACTIVITY AND FUNCTIONAL IMPROVEMENT IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS TREATED WITH UPADACITINIB: RESULTS FROM THE SELECT-AXIS 1 TRIAL (2020) (3)
Oral Abstracts 7: RA ClinicalO37. Long-Term Outcomes of Early RA Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach (2013) (3)
[Early diagnosis of spondyloarthritis with special attention to the axial forms]. (2005) (3)
[Diagnosis and therapy of axial spondyloarthritis including ankylosing spondylitis (Bechterew's disease)]. (2012) (3)
IDENTIFICATION OF ANTI-TNF CANDIDATES BASED ON PREDICTED RESPONSE AND REMISSION IN ANKYLOSING SPONDYLITIS (2010) (3)
Iloprost treatment in systemic sclerosis: comment on the concise communication by Tedeschi et al. (1999) (3)
Low Rate of Progression to Ankylosing Spondylitis Among Patients With Presumed Nonradiographic Axial Spondyloarthritis: Comment on the Article by Wang et al (2017) (3)
OP0063 Three months results of a double-blind placebo controlled, phase-iii clinical trial of infliximab in active ankylosing spondylitis (2001) (3)
SAT0351 Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis: 96-Week Outcomes of the Rapid-Axspa Trial (2014) (3)
OP0091 Prediction of radiographic spinal progression using biomarkers in patients with ankylosing spondylitis who are at high risk for progression (2013) (3)
Diagnosing axial spondyloarthritis: estimation of the disease probability in patients with a priori different likelihoods of the diagnosis. (2021) (3)
SAT0283 Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 4-year results from the phase iii trial, measure 2 (2017) (3)
A case of axial undifferentiated spondyloarthritis diagnosis and management (2007) (3)
SAT0362 Certolizumab Pegol Rapidly Reduces Peripheral Enthesitis and the Incidence of Tender and Swollen Joints in Patients with Active Axial Spondyloarthritis, Including Both Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis (2014) (3)
Geographical prevalence of family history in patients with axial spondyloarthritis and its association with HLA-B27 in the ASAS-PerSpA study (2022) (2)
Reply: To PMID 25545240. (2015) (2)
Long-term Tolerability and Efficacy of Golimumab in Active Non-Radiographic Axial Spondyloarthritis: Results From Open-Label Extension. (2021) (2)
Treatment Guidelines for Axial Spondyloarthritis (2019) (2)
FRI0286 Burden of the disease in axial spondyloarthritis (2013) (2)
FRI0436 Radiographic spinal progression and clinical disease activity are both relevant for the functional outcome in patients with early axial spondyloarthritis (2013) (2)
SAT0395 Similarities and differences between non-radiographic and radiographic axial spondyloarthritis in proof cohort (2017) (2)
Response to H Zeidler's comments on the INFAST study (2014) (2)
Predictive value of C-reactive protein for radiographic spinal progression in axial spondyloarthritis in dependence on genetic determinants of fibrin clot formation and fibrinolysis (2021) (2)
SP0108 Different Approaches To Drug Approval by EMA and FDA – The Example of Non-Radiographic Axial Spondyloarthritis (2016) (2)
Overview of Axial Spondyloarthritis (2014) (2)
Diagnostic evaluation of the sacroiliac joints for axial spondyloarthritis: should MRI replace radiography? (2022) (2)
THU0401 IMPACT OF BODY COMPOSITION MEASURES ON THE RESPONSE TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PATIENTS WITH ANKYLOSING SPONDYLITIS (2020) (2)
[Treat-to-target (T2T) recommendation for patients with spondyloarthritis - translation into German]. (2016) (2)
[Spondyloarthritides--new aspects of classification, diagnosis and therapy]. (2004) (2)
[Autoantibodies against centrosomes in a patient with limited systemic sclerosis with ulcera cruris and arteriopathy--case report and review of the literature]. (1997) (2)
Radiographic sacroiliitis progression in axial spondyloarthritis: central reading of 5-year follow-up data from the ASAS cohort. (2021) (2)
[Modern treatment of ankylosing spondylitis]. (2007) (2)
AB0898 Biomarker for spondyloarthritis: Autoantibodies against class II-associated invariant chain peptide (clip) (2013) (2)
What is the optimal target for a T2T approach in axial spondyloarthritis? (2021) (2)
Evaluation of the spinal pain score in AS--a psychometric analysis. (2012) (2)
Incorporation of the anteroposterior lumbar radiographs in the modified Stoke Ankylosing Spondylitis Spine Score improves detection of radiographic spinal progression in axial spondyloarthritis (2019) (2)
215. Sustained Clinical Remission in Patients with Non-Radiographic Axial Spondyloarthritis after Two Years of Adalimumab Treatment (2014) (2)
[Psoriatic onycho-pachydermo-periostitis (POPP)]. (1997) (2)
[Pathogenesis of ankylosing spondylitis-mechanisms of disease manifestation and chronicity]. (2004) (2)
Long-Term Tolerability and Efficacy of Golimumab in Active Nonradiographic Axial Spondyloarthritis : Results from the Open-Label Extension of a Randomized, Double-Blind Study (2015) (2)
THU0200 Sustained and Similar Clinical Response to Etanercept After 6 Years of Treatment in Patients with Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Long-term Results of the Esther Trial (2015) (2)
[Biomarkers in rheumatology. Biomarkers and imaging for the diagnosis and stratification of rheumatoid arthritis and spondylarthritis in the ArthroMark network funded by the Federal Ministry of Education and Research]. (2012) (2)
THU0231 Do degree of family relationship and ethnicity impact the association between a positive family history for spondyloarthritis and presence of hla-b27? results from the worldwide asas cohort (2018) (2)
OP0172 Inflammation and fatty degeneration are of similar importance for new bone formation in patients with ankylosing spondylitis treated with infliximab or other anti-TNF agents over 5 years (2013) (2)
THU0276 A randomized, open-label study to explore whether partial remission can be maintained with naproxen or no treatment in patients with early, active axial spondyloarthritis: Preliminary results of INFAST part II (2013) (2)
Improvement in Signs and Symptoms of Active Ankylosing Spondylitis Following Treatment with Anti-Interleukin (IL)-17A Monoclonal Antibody Secukinumab Are Paralleled by Reductions in Acute Phase Markers and Inflammatory Markers S100A8 and A9 (Calgranulin A and B) (2012) (2)
SAT0388 Long-Term Efficacy and Tolerability of Golimumab in Active Nonradiographic Axial Spondyloarthritis: Results of The Open-Label Extension of A Randomized, Double-Blind Study (2016) (2)
FRI0317 CONSENSUS DEFINITIONS FOR MRI LESIONS IN THE SPINE OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS: FIRST ANALYSIS FROM THE ASSESSMENTS IN SPONDYLOARTHRITIS INTERNATIONAL SOCIETY CLASSIFICATION COHORT (2020) (2)
Treatment with tumour necrosis factor inhibitors is associated with a time-shifted retardation of radiographic spinal progression in patients with axial spondyloarthritis (2022) (2)
FRI0270 Concurrent sacroiliac joint and spinal inflammation on MRI in patients with non-radiographic axial spondyloarthritis (2013) (2)
AB1266 Performance of a patient-based online-questionnaire to identify patients with axial spondyloarthritis (SPA) in patients with chronic low back pain (2013) (2)
THU0263 Development of chronic inflammatory changes on whole body magnetic resonance imaging in patients with early axial spondyloarthritis after two years of continuous treatment with etanercept – 2 year data of the esther trial (2013) (2)
Analysis of Bone Samples from Patients with Spondyloarthritides—Identifying Causes of New Bone Formation in Axial Spondyloarthritis (2015) (2)
Pathogenese der Spondyloarthritiden (2019) (2)
OP0139 A TIME-SHIFTED EFFECT OF TUMOR NECROSIS FACTOR INHIBITORS ON RADIOGRAPHIC SPINAL PROGRESSION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: LONG-TERM RESULTS FROM THE GERMAN SPONDYLOARTHRITIS INCEPTION COHORT (2021) (2)
THU0234 Long-Term Efficacy of Infliximab in Patients with Ankylosing Spondylitis – Real Life Data Confirm the Potential for Dose Reduction by Stretching Infusion Intervals (2015) (2)
FRI0379 LONG-TERM EVALUATION OF SECUKINUMAB 150 MG IN ANKYLOSING SPONDYLITIS: 5-YEAR END-OF-STUDY EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL (2019) (2)
[Modern treatment of ankylosing spondylitis]. (2007) (2)
THU0230 Performance of an online self-referral questionnaire compared to a physician-based referral approach to identify patients with a high probability of axial spondyloarthritis: results from the optiref study (2018) (2)
FRI0437 How to identify patients at high risk for rapid radiographic spinal progression early in the course of axial spondyloarthritis? (2013) (2)
[Dissemination and evaluation of ASAS/EULAR recommendations for the management of ankylosing spondylitis in Europe]. (2009) (2)
SPONDYLOARTHROPATHY. AUTHORS' REPLY (1999) (2)
[Principles of therapy in reactive arthritis]. (1994) (2)
SAT0389 FREQUENCY OF DISEASE FLARES UNDER LONG-TERM ANTI-TNF THERAPY IN PATIENTS WITH EARLY AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE ETANERCEPT VERSUS SULFASALAZINE IN EARLY AXIAL SPONDYLOARTHRITIS TRIAL (2020) (2)
OP0334 Efficacy and safety of continuing versus withdrawing adalimumab (ADA) in maintaining remission in patients with non-radiographic axial spondyloarthritis (NR-AXSPA) (2018) (2)
THU0414 Inter SPA: Sensitivity and Specifity of Autoantibodies against CD74 in Early Axial Spondyloarthritis (2016) (2)
[Therapy of rheumatoid arthritis]. (2008) (2)
OP0079 PRELIMINARY DEFINITION OF A POSITIVE MRI FOR STRUCTURAL LESIONS IN THE SACROILIAC JOINTS IN AXIAL SPONDYLOARTHRITIS (2020) (1)
Massive splenomegaly and hypersplenism in a young woman with primary Sjögren's syndrome. (2002) (1)
THU0359 Smoking was not Associated with Response to Adalimumab Therapy in Patients with Non-Radiographic Axial Spondyloarthritis (2013) (1)
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 2 Preamble]. (2014) (1)
Anti-TNF therapy and the spondyloarthritides: who should be treated? (2002) (1)
SAT0245 Elevated serum levels of sclerostin and periostin protect against syndesmophyte formation in patients with ankylosing spondylitis and high activity of systemic inflammation (2013) (1)
[Immunopathogenetic hypotheses in inflammatory rheumatic diseases]. (2001) (1)
Spondylarthropathies (including psoriatic arthritis) 244. Validity of Colour Doppler and Spectral Doppler Ultrasound of Sacroilicac Joints Againts Physical Examination as Gold Standard (2011) (1)
Editorial comment: spondyloarthritides. (2011) (1)
AB0716 SEX DIFFERENCES IN CLINICAL PHENOTYPE AND RADIOGRAPHIC DISEASE PROGRESSION IN AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE GERMAN SPONDYLOARTHRITIS INCEPTION COHORT (2020) (1)
114. SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING (MEASURE 2) (2017) (1)
[Current therapy with TNFalpha blocking agents for ankylosing spondylitis and undifferentiated spondyloarthritis]. (2004) (1)
THU0262 Sclerostin does not predict radiographic progression in patients on anti-tnf therapy – new results from the european ankylosing spondylitis (AS) infliximab cohort (EASIC) (2013) (1)
FRI0114 Reaching A Status of Low Disease Activity Spontaneously over Two Year Follow-Up in Active Patients with Non-Radiographic Axial Spondyloarthritis in Comparison to Ankylosing Spondylitis not Treated with TNF Blockers (2014) (1)
OP0343 LONGITUDINAL ASSESSMENT OF MRI OF THE SACROILIAC JOINTS IN THE ASAS CLASSIFICATION COHORT: EVOLUTION OF DIAGNOSTIC FEATURES AND PREDICTIVE UTILITY FOR AXIAL SPONDYLOARTHRITIS: (2019) (1)
Diagnosis of Axial Spondyloarthritis (2014) (1)
[Development of quality standards for patients with axial spondyloarthritis for use in Germany]. (2021) (1)
Recent Advances in the Pharmacotherapy of Spondyloarthropathies (2002) (1)
THU0276 Mri lesion definitions in axial spondyloarthritis: a consensus reappraisal from the assessments in spondyloarthritis international society (ASAS) (2018) (1)
FRI0397 The Diagnostic Value of The Symptom of Inflammatory Back Pain in Axial Spondyloarthritis in The Rheumatology Setting (2016) (1)
SAT0375 Certolizumab Pegol for The Treatment of Axial Spondyloarthritis: 4-Year Outcomes from The Rapid-AXSPA Trial (2016) (1)
[Effectiveness of biological agents in ankylosing spondylitis]. (2005) (1)
O05 Secukinumab Significantly Improves Physical Function, Quality of Life, Fatigue and Work Productivity in Subjects with Active Ankylosing Spondylitis Treated for Up to 52 Weeks in the Phase III Measure 2 Study (2016) (1)
SAT0396 Secukinumab Provides Sustained Improvements in The Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from A Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing (Measure 2) (2016) (1)
SAT0305 ASSOCIATION OF SKIN PSORIASIS WITH CLINICAL AND RADIOGRAPHIC CHARACTERISTICS IN AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE GERMAN SPONDYLOARTHRITIS INCEPTION COHORT (2019) (1)
Assessment of Spondyloarthritis International Society Endorsed Recommendations for Early Referral of Patients Suspected for Axial Spondyloarthritis. (2014) (1)
[Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF alpha-antagonists]. (2003) (1)
[Epidemiology and patient management in the area of spondyloarthritis]. (2002) (1)
Development and validation of an artificial intelligence approach for the detection of radiographic sacroiliitis (2020) (1)
[Diagnosis and antibiotic treatment of reactive arthritis]. (2002) (1)
Comparing 2 referral strategies to diagnose axial spondyloarthritis: the recognizing and diagnosing ankylosing spondylitis reliably study (2011) (1)
Severe destructive beta 2-microglobulin arthropathy after 28 years of hemodialysis. (1997) (1)
Osteoporosis due to steroid therapy (2001) (1)
Speaker Abstracts (SP01–SP50) (2012) (1)
OP0080 Higher Serum Level of Leptin Might Be Responsible for Less Structural Damage in The Spine in Female Patients with Ankylosing Spondylitis (2016) (1)
[Cytokine expression in coxarthrosis and knee osteoarthritis]. (1998) (1)
FRI0191 Similarities and differences between osteitis condensans ilii and axial spondyloarthritis patients presenting with chronic back pain in a rheumatology setting (2018) (1)
FRI0456 Performance of magnetic resonance imaging for the detection of chronic structural changes in the sacroiliac joints as compared to conventional x-rays in axial spondyloarthritis (2013) (1)
Relation of α2-Antiplasmin Genotype and Genetic Determinants of Fibrinogen Synthesis and Fibrin Clot Formation with Vascular Endothelial Growth Factor Level in Axial Spondyloarthritis (2020) (1)
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 7 Disease activity and prognosis of spondyloarthritis]. (2014) (1)
Spondyloarthritides - classification, diagnostic procedures and therapy (2004) (1)
THU0365 THE IMPACT OF UVEITIS, PSORIASIS AND INFLAMMATORY BOWEL DISEASE ON MUSCULOSKELETAL DISEASE ACTIVITY AND FUNCTION IN AXIAL SPONDYLOARTHRITIS: A POPULATION-BASED ANALYSIS OF INSURANCE CLAIMS LINKED TO PATIENT SURVEY DATA (2019) (1)
THU0240 Early Clinical Response is a Better Predictor of Long-Term Remission than Baseline Disease Characteristics Following Adalimumab Treatment in Peripheral Spondyloarthritis (2015) (1)
Identification of clinical phenotypes of peripheral involvement in patients with spondyloarthritis, including psoriatic arthritis: a cluster analysis in the worldwide ASAS-PerSpA study (2021) (1)
SAT0022 Successful treatment of patients with severe undifferentiated spondyloarthropathy with the anti-tnfa antibody infliximab (2001) (1)
[Explanatory models for HLA-b27 association of reactive arthritis as a paradigm for spondyloarthropathy]. (1996) (1)
FRI0194 Ankylosing spondylitis disease activity score (ASDAS) based on a quick quantitative crp assay performs similarly well to asdas based on conventional crp in patients with axial spondyloarthritis (2018) (1)
OP0141 No Signs for Direct Bone Formation or Endochondral Ossification at the Entheses in Facet Joints from Ankylosing Spondylitis Patients (2013) (1)
CD8+ T cells of reactive arthritis patients recognize a peptide from the 60 kDa heat shock protein of Yersinia (1997) (1)
THU0361 DIAGNOSTIC PERFORMANCE OF MRI LESIONS IN THE SACROILIAC JOINTS ACCORDING TO UPDATED ASAS LESION DEFINITIONS: A CENTRAL READER ASSESSMENT OF MRI SCANS FROM THE ASSESSMENTS IN SPONDYLOARTHRITIS CLASSIFICATION COHORT (2019) (1)
Two-year follow-up results after re-administration of etanercept in active ankylosing spondylitis (2005) (1)
Interactions of pathogens with the host immune system: implications for the pathogenesis of reactive arthritis. (1999) (1)
BHPR research: qualitative1. Complex reasoning determines patients’ perception of outcome following foot surgery in rheumatoid arhtritis (2012) (1)
Regulation of Regulatory T Cells (1993) (1)
OP0045 Clinically Active Non-Radiographic Axial Spondyloarthritis Patients who Initially have a Negative MRI and Normal CRP May Develop a Positive MRI or Elevated CRP at a Later Timepoint (2015) (1)
[Current status of therapeutic approaches in spondyloarthropathies]. (2001) (1)
FRI0424 Role of baseline c-reactive protein in response to infliximab plus naproxen vs naproxen alone in patients with axial spondyloarthritis in the infast study (2013) (1)
Comment on the article 'Reactive arthritis, beta-haemolytic Streptococcus and Staphylococcus aureus' by D. N. Leitch and C. D. Holland. (1997) (1)
SAT0353 Meta-Analysis Comparing the Efficacy of Tnf-Blockers in as and Nr-Axspa Patients (2014) (1)
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 5 Initial diagnosis/referral strategy]. (2014) (1)
SAT0372 Clinical and Imaging Efficacy of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: 48-Week Treatment Data (2014) (1)
Twenty years of clinical trials in axial spondyloarthritis: what can we learn for the future? (2021) (1)
Positive and negative predictive values from published studies can be misleading for decision-making in clinical practice. (2006) (1)
OP0097 Cigarette smoking predicts radiographic progression in the spine in patients with axial spondyloarthritis in a dose-dependent manner (2013) (1)
Oral tolerance from a general perspective, and the possible role of side-effects in the gut (1995) (0)
Clinician's Manual on Ankylosing Spondylitis (2011) (0)
Treg + Alloantigen-Reactive Natural Foxp3 T Cells Enabling Direct Isolation of Regulatory T Cells (Treg) and Conventional Expression Pattern Delineates Activated A Converse 4-1BB and CD40 Ligand (2012) (0)
THU0366 MAGNETIC RESONANCE IMAGING IN COMPARISON WITH CONVENTIONAL RADIOGRAPHY FOR DETECTION OF STRUCTURAL CHANGES TYPICAL FOR SPA – DATA FROM THE ASSESSMENT OF SPONDYLOARTHRITIS INTERNATIONAL SOCIETY (ASAS) COHORT (2019) (0)
Sweet ’ s syndrome in a patient with acute Crohn ’ s colitis and longstanding ankyl-osing spondylitis (2006) (0)
OP0243 Predictors of remission at week 12 in patients with non-radiographic axial spondyloarthritis receiving open-label adalimumab treatment in the ability-3 study (2017) (0)
The After 2 Years of Tumor Necrosis Factor Inhibitor Therapy Ankylosing Spondylitis Identified by Magnetic Resonance Imaging: Changes Vertebral Erosions Associated with Spinal Inflammation in Patients with (2013) (0)
Assessment of agreement of expert opinion on clinical features in axial spondyloarthritis (SpA) (2005) (0)
FRI0303 PERIPHERAL SYMPTOMS ARE ASSOCIATED WITH LESS SPINAL RADIOGRAPHIC PROGRESSION IN PATIENTS WITH EARLY AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE GERMAN SPONDYLOARTHRITIS INCEPTION COHORT (2020) (0)
Artritis reactiva por Mycoplasma pneumoniae (2016) (0)
THU0369 Secukinumab 150mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from phase iii trial, measure 2 (2017) (0)
Implementing an automated monitoring process in a digital, longitudinal observational cohort study (2021) (0)
OP0137 TUMOR NECROSIS FACTOR INHIBITORS SHOW A DELAYED EFFECT ON RADIOGRAPHIC SACROILIITIS PROGRESSION IN PATIENTS WITH EARLY AXIAL SPONDYLOARTHRITIS: 10-YEAR RESULTS FROM THE GERMAN SPONDYLOARTHRITIS INCEPTION COHORT (2021) (0)
[New and old therapeutic options in ankylosing spondylitis--is there an indication for sulfasalazine?]. (2002) (0)
SAT0272 Whole body MRI in active non-radiographic axial spondyloarthritis and ankylosing spondylitis – distribution of findings in the axial skeleton (2013) (0)
Imaging in Axial Spondyloarthritis (2012) (0)
[Diagnosis of rheumatoid arthritis]. (1996) (0)
POS0296 DOSING OF BDMARDS IN AXSPA AND PSA IN A REAL WORLD SETTING (2021) (0)
HLA-B 27 / Peptide Complexes HLA-B 27 Contributes to T Cell Recognition Residue of 67 The Solvent-Inaccessible (2004) (0)
FRI0292 TREATMENT RESPONSE TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IS ASSOCIATED WITH FAVORABLE CHANGES OF THE BODY COMPOSITION IN PATIENTS WITH ANKYLOSING SPONDYLITIS (2020) (0)
3.4 Chlamydia infections and arthritis (2000) (0)
Ankylosing Spondylitis – Diagnostic Approach and Treatment Options in a Frequently Overlooked Cause of Low Back Pain (2005) (0)
3 Rheumatoide Arthritis (Chronische Polyarthritis) (1991) (0)
SAT0287 What are the economic implications of anti-tnf therapy in patients with axial spondyloarthritis? – results of a health insurance claims data analysis (2018) (0)
SAT0231 Baseline Elevated Serum Levels of Calprotectin as Independent Marker for Radiographic Spinal Progression in Ankylosing Spondylitis (2013) (0)
arthritis and psoriasis? international working group: a model for psoriatic ASessment in Ankylosing Spondylitis (ASAS) (2006) (0)
[New aspects in the area of spondyloarthritis. Report on the 6(th) International Congress on Spondyloarthropathies]. (2009) (0)
T cell responses in reactive and Lyme arthritis (1998) (0)
AB0888 Distribution of active inflammatory lesions on magnetic resonance imaging of the the sacroiliac joints and the spine in patients with early axial spondyloarthritis –results of the esther trial at baseline (2013) (0)
SUSTAINED EFFICACY OF ADALIMUMAB IN NON-RADIOGRAPHIC AXIAL SPONDYLARTHRITIS : WEEK 68 RESULTS FROM ABILITY 1 (2012) (0)
SAT0288 Secukinumab demonstrates rapid and sustained efficacy in ankylosing spondylitis patients with normal or elevated baseline crp levels: pooled analysis of two phase 3 studies (2018) (0)
AB0847 Comparison of treatment responses to TNF-blockers in axial spondyloarthritis patients with short vs long symptom duration (2013) (0)
ORAL TYPE I 1 COLLAGEN TREATMENT IN EARLY RHEUMATOID ARTHRITIS A Double-Blind , Placebo-Controlled , Randomized Trial (2005) (0)
OP0025 Identification of predictors of structural damage progression in the sacroiliac joints in patients with early axial spondyloarthritis on a long-term anti-tnf treatment (2018) (0)
OP0026 Adalimumab serum concentration fails to predict achievement of sustained remission or absence of flare for patients with non-radiographic axial spondyloarthritis in the ability-3 study (2018) (0)
SAT0355 Observed Incidence Rates of Uveitis following Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis (2014) (0)
SAT0271 Predictors of physical function and mobility in nonradiographic axial spondyloarthritis and ankylosing spondylitis (2013) (0)
Chapter 38 – Spondyloarthritides (2014) (0)
OP0172 No Differences in the Rate of New Fatty Lesions Following Resolution of Inflammation on MRI Between Infliximab Added to Naproxen and Naproxen Alone in Early Axial Spondyloarthritis: Results from the Part I of the Infast Study (2015) (0)
FRI0169 Elevated LBP Levels and in Vivo Activation of Monocytes as Potential Indicators of Bacterial Translocation in Axial Spondyloarthritis (2014) (0)
[Reactive arthritis. New aspects of pathogenesis, diagnosis and therapy]. (1997) (0)
THU0218 Baseline Demographic and Disease Characteristics Associated with Response to Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis (2015) (0)
" .'l~J("I~"~"_~'~".(..: (1997) (0)
SAT0265 Ratio of non-radiographic and radiographic axial spondyloarthritis in patients referred because of back pain is dependent on symptom duration (2013) (0)
FRI0175 Rates and predictors of radiographic sacroiliitis progression after central reading in patients with axial spondyloarthritis from the asas cohort: a 5-year follow-up study (2018) (0)
FRI0435 Comparison between central and local assessment of radiographic sacroiliitis in patients with recently diagnosed axial spondyloarthritis in proof study (2017) (0)
FRI0323 THE PRESENCE OF SPONDYLOARTHRITIS IS ASSOCIATED WITH HIGHER CLINICAL DISEASE ACTIVITY IN PATIENTS WITH EARLY CROHN’S DISEASE: RESULTS OF A PROSPECTIVE COHORT STUDY (2020) (0)
FRI0173 Identification of a typical pattern of mri lesions of sacroiliac joints in patients with osteitis condensans ilii as compared to axial spondyloarthritis (2018) (0)
Aetiological role ofbacteria associated withreactive arthritis inpauciarticular juvenile chronic arthritis (1992) (0)
[Diagnosis of reactive arthritis]. (2004) (0)
Adalimumab sustains improvement in spinal mobility in as patients through 104 weeks - Results from atlas (2008) (0)
[Reactive arthritis: pathogenesis, diagnosis and therapy]. (1992) (0)
8 Mischkollagenose (Mixed connective tissue disease, Sharp-Syndrom) (1991) (0)
SAT0342 Arthritis and Enthesitis Remission during Adalimumab Treatment in Peripheral Spondyloarthritis: Year-2 Results from Ability-2 (2014) (0)
174 Secukinumab demonstrates consistent safety over long-term exposure up to three years in patients with active ankylosing spondylitis: pooled analysis of three Phase III trials (2018) (0)
Reply (2015) (0)
261 Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 4-year results from the Phase 3 trial, MEASURE 2 (2018) (0)
[Early diagnosis of rheumatic diseases--relevance and challenges]. (2005) (0)
Oral abstracts 1: SpondyloarthropathiesO1. Detecting axial spondyloarthritis amongst primary care back pain referrals (2012) (0)
Ankylosierende Spondylitis (2006) (0)
Long term IL-17A inhibition by secukinumab leads to reduced spinal inflammation and unchanged fatty lesions in patients with ankylosing spondylitis (2013) (0)
BSR AND BHPR ORAL PRESENTATION OF ABSTRACTS ORAL ABSTRACTS 1: SPONDYLOARTHROPATHIES (2012) (0)
Years of Continuous Etanercept Treatment Imaging of Enthesitis in Patients with Early Axial Spondyloarthritis during 3 Comparison of Clinical Examination versus Whole-body Magnetic Resonance (2016) (0)
HLA-B 27-Associated Diseases Proteome with Possible Relevance to Chlamydia trachomatis Peptides from the Identification of HLA-B 27-Restricted Kloetzel and (2001) (0)
T cell response in -induced reactive arthritis. (2004) (0)
THU0359 WHAT IS THE LEVEL OF AGREEMENT BETWEEN LOCAL AND CENTRAL READERS IN THE DETECTION OF ACTIVE AND STRUCTURAL LESIONS ON MRI TYPICAL OF AXIAL SPONDYLOARTHRITIS? DATA FROM THE ASAS CLASSIFICATION COHORT STUDY (2019) (0)
Rheumatic Disease Clinics of North America. Spondyloarthritis. Preface. (2012) (0)
Quantitative ultrasound and bone mineral density measurements at the proximal phalanges in rheumatoid arthritis (2006) (0)
EARLY EFFECT OF SECUKINUMAB IN REDUCING SPINAL INFLAMMATION AS DETECTED BY MAGNETIC RESONANCE IMAGING IN PATIENTS WITH ANKYLOSING SPONDYLITIS (2012) (0)
First Validation of Consensus Definitions for MRI Lesions in the Sacroiliac Joint By the Assessments in Spondyloarthritis International Society MRI Group (2018) (0)
THU0274 Assessment of radiographic sacroiliitis on antero-posterior lumbar radiographs as compared to conventional pelvic radiographs in patients with axial spondyloarthritis (2018) (0)
Parameters contributing to inflammatory back pain (IBP) according to experts (2005) (0)
FRI0113 Persistently High Disease Activity According to the ASDAS is Associated with Accelerated Radiographic Spinal Progression in Patients with Axial Spondyloarthritis (2014) (0)
I59. New Biologic Treatments for Ankylosing Spondylitis (2014) (0)
SAT0559 High Expression of Cyclooxygenase-2, Prostaglandin E2 and Prostaglandin E2 Receptor Ep4 in Zygapophyseal Joints of Patients with Ankylosing Spondylitis (2014) (0)
THU0407 Baseline Results from Proof – A 5-Year Observational Study of Long-Term Disease Outcome in Axial Spondyloarthritis (2016) (0)
Response to ‘Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happier’ by Alunno et al (2018) (0)
FRI0282 Insights into progression of structural damage of sacroiliac joints in patients with axial spondyloarthritis: Introduction of new scoring system for radiographic sacroiliitis (2013) (0)
[Basic therapeutics in the management of various forms of arthritis]. (1998) (0)
[Rheumatologic patient management and research in Berlin at the intersection between East and West]. (1995) (0)
Better performance of the Leeds and Sparcc enthesitis indices compared to the mases in patients with peripheral spondyloarthritis during treatment with adalimumab (2014) (0)
SAT0263 Predictors of remission maintenance and successful therapy discontinuation in patients with non-radiographic axial spondyloarthritis (NR-AXSPA) who achieved sustained remission on open-label adalimumab (ADA) treatment (2018) (0)
229. Relationship Between MRI AND Clinical Remission in Patients with Non-Radiographic Axial Spondyloarthritis After Two Years of Adalimumab Therapy (2014) (0)
OR.79. Twist1-a Regulator of Th1 Effector Function in Chronic Inflammatory Diseases (2006) (0)
Spondyloarthritis and related conditions (2020) (0)
FRI0154 Added value of biomarkers compared to routine clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis (2018) (0)
Etanercept: A Viewpoint by Joachim Sieper (2004) (0)
THU0273 Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after one year of treatment with etanercept - results of the esther trial (2013) (0)
[New aspects of treatment and prophylaxis of gastrointestinal side effects caused by non-steroidal-antiinflammatory drugs]. (1999) (0)
118 – Management of ankylosing spondylitis/axial spondyloarthritis (2015) (0)
OP0248 Potential differences in axial spondyloarthritis disease activity categorization using different minimum values for high-sensitivity crp in ankylosing spondylitis disease activity score calculation and different definitions of disease flare (2018) (0)
THU0350 Reduced Thickness and Invasion of the Subchondral Bone Plate by Fibrous Tissue are Hallmarks of Joint Remodeling in Ankylosing Spondylitis (2013) (0)
Associated with Spondyloarthropathy Cell Epitopes in HLA-B27 Transgenic Mice Identification of Novel Human Aggrecan T (2013) (0)
Clinical manifestations of ankylosing spondylitis (2011) (0)
Reply (2015) (0)
SAT0350 Quality of Life with Etanercept in Early Non-Radiographic Axial Spondyloarthritis: 24 and 48-Week Data from A Randomized, Double-Blind, Placebo-Controlled Trial (2014) (0)
THU0343 No Upregulation of IL-6 at Different Sites in Facet Joints of Patients with Ankylosing Spondylitis Compared to Controls (2013) (0)
Current therapy with TNF blocking agents for ankylosing spondylitis and undifferentiated (2004) (0)
Diagnosis of ankylosing spondylitis (2011) (0)
2008for the treatment of rheumatic diseases, Updated consensus statement on biological (2008) (0)
Etanercept: A viewpoint (2004) (0)
Sa.56. IL-2 Receptor Common γ-Chain Signalling Required for Cytokine Induced Human IFNγ+ Effector Th Cells That Participate in Rheumatoid Arthritis Inflammation (2006) (0)
7 Polymyositis / Dermatomyositis (1991) (0)
Overview of ankylosing spondylitis (2009) (0)
Detailed hand bone mineral density analyses in rheumatoid arthritis A predictor of future bone erosions (2000) (0)
SAT0255 Predictive and protective role of adipokines in radiographic spinal progression in patients with ankylosing spondylitis (2013) (0)
Autologous K 1 Epitopes Target Darwinian Positively Selected Cytotoxic T Lymphocytes Recognize and Kaposi ' s Sarcoma-Associated Herpesvirus (2003) (0)
[The diagnosis of reactive arthritis. The possibilities and limits]. (1993) (0)
OP0249 The contribution of structural mri lesions to detection of sacroiliitis in patients in the assessments in spondyloarthritis international society (ASAS) classification cohort (2018) (0)
OP0253 STRUCTURAL DAMAGE IN AXIAL SPONDYLOARTHRITIS: IS THERE A PREFERRED WAY TO ASSESS PROGRESSION OVER TIME? (2021) (0)
A4.11 Baseline Elevated Serum Levels of Calprotectin as Independent Marker for Radiographic Spinal Progression in Ankylosing Spondylitis (2013) (0)
Socioeconomic aspects of ankylosing spondylitis (2011) (0)
List of Contributors (2020) (0)
SP0146 Non anti-TNF biologics in axial spondyloarthritis (2013) (0)
Reactive Arthritis. Reaktive Arthritis (1999) (0)
CLINICAL RESPONSE AND PARTIAL REMISSION SUSTAINED THROUGH 3 YEARS OF ADALIMUMAB TREATMENT IN THE ATLAS TRIAL (2009) (0)
SP0016 The spondyloarthropathies as a paradigm for the induction of an autoimmune response by bacteria (2001) (0)
[Lessons learnt from 15 years of investigator-initiated trials on axial spondyloarthritis]. (2015) (0)
Clinical Manifestations of Axial Spondyloarthritis (2014) (0)
Chlamydia infections and arthritis (2000) (0)
9 Sjögren-Syndrom (1991) (0)
chronic arthritis . reactive arthritis in pauciarticular juvenile Aetiological role of bacteria associated with (2004) (0)
A3.19 The miR-148a is Induced by TWIST1 and TBET and Promotes the Survival of Effector Memory T Helper 1 Lymphocytes by Regulating the Proapoptotic Gene BIM (2013) (0)
[Presentation of the Center of Competence in Berlin]. (2002) (0)
SAT0422 Long-Term anti-TNF Treatment Is Associated with Reduction of Progression of Radiographic Changes in The Sacroiliac Joints in Patients with Non-Radiographic Axial SpA: Six-Year Results of The Esther Trial (2016) (0)
FRI0193 Osteoblasts Promote New Bone Formation at Sites of Cartilage and Bone Erosions While Fat Marrow is Found Within the Subchondral Bone Marrow in Ankylosing Spondylitis (2015) (0)
Assessment of radiographic sacroiliitis in anteroposterior lumbar vs conventional pelvic radiographs in axial spondyloarthritis. (2020) (0)
OP0244 High Expression of Prostaglandin E2 in Zygapophyseal Joints of Patients with Ankylosing Spondylitis and Osteoarthritis (2013) (0)
SAT0031 Fine epitope mapping of immunodominant peptide epitopes by affinity matrix technology using yersinia-hsp60-specific synovial cd4+ t-cells in reactive arthritis (rea) patients (2001) (0)
Proteome with Possible Relevance to Chlamydia trachomatis Peptides from the Identification of HLA-B27-Restricted (2015) (0)
[The clinical concept of spondyloarthropathies]. (1997) (0)
Synovial cell production of IL-26 induces bone mineralization in spondyloarthritis (2017) (0)
Rheumatoid arthritis and other inflammatory joint diseases (animal models) (PP-037) (2010) (0)
Commented glossary for rheumatic spinal diseases. Authors' reply (1996) (0)
SAT0562 Comparison of MRI and Radiography in Detecting Structural Damage of The Sacroiliac Joints in Patients with Chronic Low Back Pain Using Low-Dose CT as Standard of Reference – Results from The Simact Study (2016) (0)
Comparison of Radiography and MRI to Detect Structural Lesions of the Sacroiliac Joints: The SIMACT Study (2017) (0)
T cell response in Shigella-induced reactive arthritis (2004) (0)
THU0344 Reduced LPS-Induced IL-6 Production by Monocytes in Whole Blood Stimulations in Patients with Ankylosing Spondylitis (2013) (0)
[Obituary for Prof. Dr. Ernst Feldtkeller who was recipient of the DGRh Kussmaul Medal honored by the German Society for Rheumatology (DGRh)]. (2023) (0)
THU0388 Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results from the 28-week open-label period of the ability-3 study (2017) (0)
FRI0199 Five-Year Follow-Up of Radiographic Sacroiliitis: Progression as Well as Improvement? (2015) (0)
[Preliminary consensus statement on glucocorticoid-induced osteoporosis]. (2001) (0)
Patients Treated with Adalimumab for Active Ankylosing Spondylitis Effectiveness , Safety , and Predictors of Good Clinical Response in 1250 (0)
OP0247 Reduction of radiographic spinal progression in patients with ankylosing spondylitis treated with non-steroidal anti-inflammatory drugs is most evident in the presence of syndesmophytes and active systemic inflammation (2013) (0)
Basic therapy in the treatment of arthritis (1998) (0)
FRI0198 Which factors influence psychological well-being of patients with axial spondyloarthritis? – data from a cross-sectional survey linked to insurance claims (2018) (0)
THU0251 Characteristics of newly diagnosed axial spondyloarthritis patients in rheumatology practices across germany (2018) (0)
Clinical and epidemiological research (2011) (0)
OP0092 Differential systemic and synovial TH1 cell reactivity towards escherichia coli antigens in patients with ankylosing spondylitis and rheumatoid arthritis (2013) (0)
SAT0423 Patient-Reported Quality of Life in Patients with Baseline Objective Signs of Inflammation and Active Nonradiographic Axial Spondyloarthritis Treated with Golimumab: Results of The Open-Label Extension of A Randomized, Double-Blind Study (2016) (0)
New treatment options in ankylosing spondylitis: a role for anti-TNF (cid:225) therapy (0)
Residue Cys-67 of HLA-B27 contributes to antigen presentation and T cell recognition of HLA-B27 restricted T cell epitopes. (2004) (0)
[History of the biologics treatment of axial spondylarthritis-Part 2]. (2022) (0)
SAT0276 Comparison of inflammatory back pain criteria as diagnostic tool in ankylosing spondylitis and early axial spondyloarthritis (2013) (0)
Progression of Radiographic Sacroiliitis in Patients with Axial Spondyloarthritis from the Assessment of Spondyloarthritis International Society Cohort on Central Reading - Five-Year Data (2018) (0)
AB0870 Whole body MRI findings of non axial manifestations in early axial spondyloarthritis – results of the esther trial at baseline (2013) (0)
Spondyloarthritis Detection of Chronic Structural Changes in Sacroiliac Joints in Axial Magnetic Resonance Imaging Compared to Conventional Radiographs for (2013) (0)
THU0379 Clinical Disease Activity Measures Are Associated with Radiographic Spinal Progression in Early Axial Spondyloarthritis (2016) (0)
[Pathogenesis and therapy of steroid-induced osteoporosis]. (2001) (0)
Long-term antibiotic treatment in reactive arthritis and undifferentiated oligoarthritis Results of a double-blinded placebo-controlled randomized study (1997) (0)
Ankylosing spondylitis: immunophenotypical characteristics of peripheral blood and synovial fluid compartments (2010) (0)
FRI0423 Effective prevention of new inflammatory bony lesions on magnetic resonance imaging in patients with early axial spondyloarthritis during treatment with etanercept over 2 years - data of the esther trial (2013) (0)
Conserved Bacterial Proteins: Implications for the Pathogenesis of Reactive Arthritis (1997) (0)
List of Contributors (2019) (0)
THU0199 Functional Status Remains Stable Despite Continuous Radiographic Spinal Progression Over Ten Years in Patients with Ankylosing Spondylitis Receiving Anti-TNF Therapy (2015) (0)
SAT0391 DEPRESSIVE SYMPTOMS ARE ASSOCIATED WITH HIGHER DISEASE ACTIVITY AND WORSE FUNCTIONAL STATUS IN AXSPA: A CROSS-SECTIONAL ANALYSIS FROM RABBIT-SPA (2020) (0)
Reply: To PMID 25154344. (2015) (0)
SP0126 How to Treat (HOT) Spondyloarthritis? (2014) (0)
SAT0240 New Inflammatory Lesions in Axial Spondyloarthritis are More Likely to Occur in the Areas Already Affected by Inflammation in the Past (2015) (0)
The Sensitivity to Change of the ASAS Health Index in an Observational Real-Life Cohort Study (2022) (0)
The role of B27 and other genes associated with ankylosing spondylitis (2006) (0)
SAT0399 Efficacy of Golimumab for Nonradiographic Axial Spondyloarthritis: Subgroup Analysis by Baseline MRI and C-Reactive Protein Status (2016) (0)
[Reactive arthritis: practical procedure in diagnosis and problematic aspects of antibiotic therapy]. (2003) (0)
[Antibiotics in the treatment of arthritis]. (1998) (0)
[The off-label-prescription of TNF-alpha blocking agents for spondyloarthropathies in the context of recent statement by a German federal court]. (2002) (0)
262 Secukinumab demonstrates rapid and sustained efficacy in ankylosing spondylitis patients with normal or elevated baseline C-reactive protein levels: pooled analysis of two Phase 3 studies (2019) (0)
chronic autoimmune inflammation secreting effector-memory Th-cells in γ Cytokine-induced human IFN (2013) (0)
SAT0254 Immunohistological analysis of chondrocytes in facet joints from anklyosing spondylitis patients (2013) (0)
Anti-TNF-α therapy monitoring in chronic rheumatic diseases by cytometric profiling of peripheral blood cells (2011) (0)
THU0379 Impact of time since diagnosis, age, and number of prior non-steroidal anti-inflammatory drugs on 52-week clinical response to adalimumab in patients with ankylosing spondylitis (2017) (0)
SP0099 Which Drugs Modify the Course of Axial Spondyloarthritis? (2015) (0)
[From uncertainty to evidence : modern statistics in rheumatology]. (2015) (0)
opinion including uncertainty appraisal (part I): classification of paper patients by expert classification criteria for axial spondyloarthritis SpondyloArthritis international Society The development of Assessment of (2009) (0)
Spondyloarthropathies (Including Psoriatic Arthritis) [40–69] 40. Eagle's Syndrome: An Unusual Association with Sero-Negative Arthropathy (2010) (0)
Etanercept for the treatment of axial spondyloarthritis (2013) (0)
THU0232 Is a positive family history of spondyloarthritis relevant for diagnosing axial spondyloarthritis once hla-b27 status is known? data from the asas, desir and space cohorts (2018) (0)
THU0286 Clinical efficacy and safety of infliximab – first results after a decade of continuous treatment in ankylosing spondylitis (2013) (0)
FRI0418 How important is the assessment of asdas in the long-term evaluation of disease activity in ankylosing spondylitis? a comparison with currently used clinical parameters (2013) (0)
ORAL TYPE I1 COLLAGEN TREATMENT IN EARLY RHEUMATOID ARTHRITIS (1996) (0)
THU0270 European ankylosing spondylitis (AS) infliximab cohort (EASIC) long-term extension: Efficacy and safety of infliximab over a time period of more than 7 years in patients with AS (2013) (0)
SAT0371 Ustekinumab Treatment in Ankylosing Spondylits (AS) Patients Does not Modulate Effector CD4+ T Cell Frequencies Including TH17 Cells (2014) (0)
Chapter 22 – Pathogenesis of Reactive Arthritis (2007) (0)
Detecting radiographic sacroiliitis using deep learning with expert-level accuracy in axial spondyloarthritis (2020) (0)
FRI0207 The incorporation of the antero-posterior lumbar spine view in the modified stoke ankylosing spondylitis spine scoreonly marginally improves detection of radiographic spinal progression in axial spondyloarthritis (2018) (0)
Reply to the editorial: Can we currently and confidently assess the true burden of illness due to non-radiographic axial spondyloarthritis? by S. van der Linden and M.A. Khan. (2016) (0)
FRI0128 Utility of Enthesitis Assessments in Peripheral Spondyloarthritis – Data from the Ability-2 Trial (2014) (0)
Rheumatoid arthritis and other inflammatory joint diseases (human studies) (PP-036) (2010) (0)
The divergent TH1/TH2 cytokine pattern in infectious arthritides and its regulation by cytokines or anti-cytokines in vitro (1997) (0)
FRI0425 Analysis of cellular composition and cytokine expression in the subchondral bone marrow in ankylosing spondylitis (2017) (0)
[Early diagnostics and therapy of spondyloarthritis including psoriatric arthropathy]. (2012) (0)
P193 Clinical features of patients with active ankylosing spondylitis who did not respond to adalimumab but responded to ixekizumab: a post-hoc analysis (2021) (0)
[History of the treatment of axial spondylarthritis with biologics-Part 1]. (2022) (0)
OP0216 Elevated Serum Level of the Vascular Endothelial Growth Factor Predicts Radiographic Spinal Progression in Patients with Axial Spondyloarthritis (2013) (0)
THU0209 Responder vs Non-Responder Baseline Characteristics and Early Response in Patients with Non-Radiographic Axial Spondyloarthritis (2015) (0)
THU0194 Serum Biomarkers Associated with Disease Activity and Response to Ustekinumab in Patients with Ankylosing Spondylitis in the Topas Study (2015) (0)
Clinically Relevant Difference ? What Is the − − Classification and Diagnosis of Axial Spondyloarthritis (2014) (0)
SAT0384 REPLACEMENT OF RADIOGRAPHIC SACROILITIS BY MRI STRUCTURAL LESIONS: WHAT IS THE IMPACT ON CLASSIFICATION OF AXIAL SPONDYLOARTHRITIS IN THE ASAS CLASSIFICATION COHORT? (2020) (0)
[25 years HLA B27--report on the "B27 and Beyond" NIH Conference]. (1999) (0)
effector memory T helper cells secrete IfN-g upon stimulation with cytokines: a role in chronic inflammation (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Joachim Sieper?

Joachim Sieper is affiliated with the following schools:

Joachim Sieper's Academic­Influence.com Rankings

Joachim Sieper's Degrees

Why Is Joachim Sieper Influential?

Joachim Sieper's Published Works

Published Works

What Schools Are Affiliated With Joachim Sieper?

Joachim Sieper's AcademicInfluence.com Rankings